Elevated serum interleukin-6 associated with a failure in B cell differentiation in common variable immunodeficiency

J Allergy Clin Immunol. 1990 Oct;86(4 Pt 1):512-21. doi: 10.1016/s0091-6749(05)80207-6.

Abstract

Interleukin-6 (IL-6/B cell stimulatory factor 2) has been found to drive activated human B-lymphocytes through the final stages of differentiation to become immunoglobulin-producing cells. Most patients with common variable immunodeficiency (CVI) have B-lymphocytes that fail to differentiate into high-rate immunoglobulin-secreting cells in vivo and in vitro. In view of (1) the known effects of IL-6 to promote B-lymphocyte terminal differentiation and (2) the defect in differentiation in B-lymphocytes of patients with CVI, we believed that it was important to analyze the role of this cytokine in patients with CVI. Using an IL-6-dependent murine hybridoma cell line in a bioassay, serum IL-6 levels were determined in 17 patients with CVI and in eight normal control subjects. Thirteen of the 17 patients with CVI exhibited serum IL-6 levels that were twofold to 18-fold higher than the range (mean, +2 SD) of normal control subjects. Spontaneous IL-6 production by peripheral blood mononuclear cells (PBMC) of patients with CVI was significantly higher than that from normal control subjects, whereas lipopolysaccharide maximally stimulated IL-6 production by PBMCs of patients with CVI or PBMCs of normal control subjects was equivalent. A substance inhibitory of IL-6 bioactivity was found in equivalent amounts in sera of both patients and normal control subjects. Sera from patients with CVI with high IL-6 bioactivity were found to have saturated this IL-6 inhibitory substance, thus resulting in large amounts of free IL-6 in the sera. These studies suggest that the failure of B cells from patients with CVI to terminally differentiate into high-rate immunoglobulin-secreting cells cannot be attributed to a decrease in the serum levels of IL-6 and that the increased circulating IL-6 levels in patients with CVI result from hyperproduction rather than decreased use of IL-6. The persistently elevated levels of IL-6 observed in some patients with CVI may secondarily result in the induction of the neoplastic and autoimmune phenomena associated with this disease.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Agammaglobulinemia / blood
  • Agammaglobulinemia / genetics
  • Agammaglobulinemia / immunology
  • B-Lymphocytes / immunology
  • B-Lymphocytes / pathology*
  • Cell Differentiation / immunology
  • Dysgammaglobulinemia / blood
  • Dysgammaglobulinemia / immunology
  • Genetic Linkage
  • Humans
  • Hybridomas / immunology
  • Hypergammaglobulinemia / blood
  • Hypergammaglobulinemia / immunology
  • IgA Deficiency
  • Immunoglobulin M
  • Immunologic Deficiency Syndromes / blood*
  • Immunologic Deficiency Syndromes / immunology
  • Interleukin-6 / blood*
  • Monocytes / immunology
  • X Chromosome

Substances

  • Immunoglobulin M
  • Interleukin-6